2023-05-01 16:17:56 ET
- SI-BONE press release ( NASDAQ: SIBN ): Q1 GAAP EPS of -$0.32 beats by $0.10 .
- Revenue of $32.71M (+45.8% Y/Y) beats by $3.55M .
- Record U.S. revenue of $30.5 million for the first quarter 2023, representing approximately 50% increase over the corresponding period in 2022
- Gross margin of 82% for the first quarter 2023
- Over 950 U.S. active surgeons in the first quarter 2023, representing approximately 40% growth over the corresponding period in 2022
- Extended first-generation iFuse patent protection to December 2025, with iFuse-3D patent coverage to September 2035
- Celebrating our 15-year commitment to pioneering solutions for sacropelvic conditions through the industry's most innovative portfolio, with over 80,000 procedures completed by over 3,000 surgeons worldwide.
- 2023 Updated Guidance: Based on the first quarter of 2023 results, SI-BONE is updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%. SI-BONE is maintaining its guidance for fiscal year 2023 gross margin of approximately 80% and improving adjusted EBITDA loss.
For further details see:
SI-BONE GAAP EPS of -$0.32 beats by $0.10, revenue of $32.71M beats by $3.55M